Morphological and Microscopic Findings: Clinical Trials

2 trials for Morphological and Microscopic Findings, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed. 2 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 42Completed 2

Follow Morphological and Microscopic Findings: new trials by email Literature Review of Morphological and Microscopic Findings trials Research Report on Morphological and Microscopic Findings

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
V501 Safety and Efficacy Study in Japanese Women Aged 16 to 26 Years (V501-110)
V501 - Cervical Cancer, Cervical Intraepithelial Neoplasia
Phase 4CompletedMerck Sharp & Dohme LLC10302011-11-252018-11-28
Photodynamic Therapy to Treat Actinic Damage in Patients With Squamous Cell Carcinoma (SCC) of the Lip
PDT prior to Mohs surgery - Actinic Cheilitis, Squamous Cell Carcinoma In-situ (SCC-is)
Phase 4CompletedTufts Medical Center342009-07-012011-07-06

Narrower conditions

Actinic cheilitis (1)  ·  Adenocarcinoma in Situ (1)  ·  Carcinoma, Squamous Cell (1)  ·  Squamous Intraepithelial Lesions (1)  ·  Uterine Cervical Dysplasia (1)  ·  Uterine Cervical Neoplasms (1)

Broader conditions

Carcinoma (2)  ·  Neoplasms (2)  ·  Neoplasms by Histologic Type (2)  ·  Neoplasms, Glandular and Epithelial (2)  ·  Pathological Conditions, Signs and Symptoms (2)  ·  Adenocarcinoma (1)  ·  Carcinoma in Situ (1)  ·  Female Urogenital Diseases (1)  ·  Female Urogenital Diseases and Pregnancy Complications (1)  ·  Genital Diseases (1)  ·  Genital Diseases, Female (1)  ·  Genital Neoplasms, Female (1)  ·  Neoplasms by Site (1)  ·  Neoplasms, Squamous Cell (1)

Interventions

Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 (1)

Sponsors

Merck Sharp & Dohme LLC (1)  ·  Tufts Medical Center (1)

Countries

United States (1)

Top investigators

Gary Rogers, M.D. (1)

Results publications

PMID 30879979

NIH funding

2015 (1)